To the Editor We congratulate Sanacora et al¹ for the publication of their consensus statement in JAMA Psychiatry. The growing amount of literature on this topic has generated interest among patients and physicians, which called for such an important document as the basis for decision-making societies, health care professionals, and regulatory authorities. Until official approval of depression as an indication, off-label uses by medical experts assuming legal, scientific, and medical hazards will increase. On the other hand, ketamine clinics or ketamine wellness centers already offer ketamine as outpatient treatment with unscientific and dangerous methods. To overcome the lack of regulation, consensus statements and their dissemination are of utmost importance.

致编辑我们祝贺 Sanacora 等人¹在JAMA Psychiatry上发表了他们的共识声明。越来越多的关于这一主题的文献引起了患者和医生的兴趣，这需要一份重要的文件作为决策协会、医疗保健专业人员和监管机构的基础。在官方批准抑郁症作为一种适应症之前，医学专家假设法律、科学和医学危害的标签外使用将会增加。另一方面，氯胺酮诊所或氯胺酮健康中心已经以不科学和危险的方法提供氯胺酮作为门诊治疗。为了克服缺乏监管，共识声明及其传播至关重要。